Plain-English translation of NCT05377034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of treatments works better than radiation therapy alone for advanced liver cancer. All patients receive a type of radiation therapy called SIRT-Y90, which uses tiny radioactive beads to target cancer cells in the liver. Half of the participants will then receive two additional immunotherapy drugs—atezolizumab and bevacizumab—while the other half will receive placebo (a fake treatment), to see if the added medications help patients live longer and stay healthier.
Advanced liver cancer is difficult to treat, and current standard treatments don't work well enough for many patients. Researchers believe that combining radiation therapy with immunotherapy drugs might help the body's immune system fight cancer more effectively than radiation alone.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups receive radiation therapy to the liver first. After that, one group receives two immunotherapy medications by IV infusion, while the other group receives placebo IV infusions. You'll have regular clinic visits and imaging scans to monitor how your cancer responds to treatment and to watch for any side effects. The study involves patients from several countries across Asia-Pacific, and the treatment plan continues for several months with ongoing follow-up appointments.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Singapore